Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses.

Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses.
复制标题

DOI:
10.1126/scitranslmed.3007097
复制
发表时间:
2013-12-18
影响因子:
17.1
通讯作者:
Edberg JC
Edberg JC
中科院分区:
医学1区
文献类型:
--
作者:
Li X;Wu J;Ptacek T;Redden DT;Brown EE;Alarcón GS;Ramsey-Goldman R;Petri MA;Reveille JD;Kaslow RA;Kimberly RP;Edberg JC

文献摘要

参考文献

被引文献

相似文献

B cells are pivotal regulators of acquired immune responses and recent work in both experimental murine models and humans has demonstrated that subtle changes in the regulation of B cell function can significantly alter immunological responses. The balance of negative and positive signals in maintaining an appropriate B cell activation threshold is critical in B lymphocyte immune tolerance and autoreactivity. FcγRIIb (CD32B), the only recognized Fcγ receptor on B cells, provides IgG-mediated negative modulation through a tyrosine-based inhibition motif which down-regulates B cell receptor initiated signaling. These properties make FcγRIIb a promising target for antibody-based therapy. Here we report the discovery of allele-dependent expression of the activating FcγRIIc on B cells. Identical to FcγRIIb in the extracellular domain, FcγRIIc has a tyrosine-based activation motif in its cytoplasmic domain. In both human B cells and in B cells from mice transgenic for human FcγRIIc, FcγRIIc expression counterbalances the negative feedback of FcγRIIb and enhances humoral responses to immunization in mice and to BioThrax® vaccination in a human Anthrax vaccine trial. Moreover, the FCGR2C-ORF allele is associated with the risk of development of autoimmunity in humans. FcγRIIc expression on B cells challenges the prevailing paradigm of uni-directional negative feedback by IgG immune complexes via the inhibitory FcγRIIb, is a previously unrecognized determinant in human antibody/autoantibody responses, and opens the opportunity for more precise personalized use of B cell targeted antibody-based therapy.
DOI: 10.4049/jimmunol.168.1.9
发表时间: 2002-01-01
影响因子: 4.4
作者:
Higuchi, T;Aiba, Y;Tsubata, T
通讯作者: Tsubata, T
DOI: 10.1073/pnas.0703354104
发表时间: 2007-06-05
影响因子: 11.1
作者:
Haga, Christopher L.;Ehrhardt, Goetz R. A.;Cooper, Max D.
通讯作者: Cooper, Max D.
DOI: 10.4049/jimmunol.1003412
发表时间: 2011-04-01
影响因子: 4.4
作者:
Horton, Holly M.;Chu, Seung Y.;Szymkowski, David E.
通讯作者: Szymkowski, David E.
DOI: 10.1038/laban1005-39
发表时间: 2005-10-01
期刊: LAB ANIMAL
影响因子: 6.9
作者:
Golde, WT;Gollobin, P;Rodriguez, LL
通讯作者: Rodriguez, LL
DOI: 10.1016/j.jmb.2010.04.001
发表时间: 2010-06-11
影响因子: 5.6
作者:
Johnson, Syd;Burke, Stephen;Bonvini, Ezio
通讯作者: Bonvini, Ezio